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Summary: The hepatocytoprotective effect of acute, turpentine-induced inflammation on experimental liver
injury, caused by thioacetamide and D-galactosamine, respectively, was studied in relation to the synthesis
of glycosaminoglycans and of heparan sulphate in hepatocytes isolated from livers of treated rats. As judged
from biochemical parameters of liver cell lesion in serum (various«cytosolic and mitochondrial enzymes, bile
acids) the extent of liver damage caused by either noxious agent was greatly attenuated under acute
inflammatory conditions. There was an inverse statistical correlation (r = —0.63 to r = —0.84) between
the functional concentration of a proteinase inhibitor protein determined with the chromogenic Substrate
assay for human a2-macroglobulin and the catalytic concentrations of various cell leakage enzymes in serum
from liver-injured rats with turpentine-generated inflammation. The strong Inhibition of heparan sulphate
synthesis in hepatocytes from injured livers (synthesis rate between 0.2 and 0.4 of that in control cell
incubations) is abolished in hepatocytes from livers exposed to the noxious agents but with acute inflamma-
tion. The latter condition alone caused a 1.8 fold increase in heparan sulphate synthesis of hepatocytes.
Heparan sulpbate was the only type of glycosaminoglycan synthesized under all conditions. The results are
discussed in view of the pathogenetic potential of heparan sulphate for liver cell necrosis.
Präventiver Effekt der akuten Entzündung auf die Leberzellnekrose und Hemmung der Heparansulfat-Synthese
in Hepatocyten
Zusammenfassung: Der hepatocytoprotektive Effekt der akuten, Terpentin-induzierten Entzündung wurde
an zwei Modellen der experimentellen Leberschädigung, der Thioacetamid- und der D-Galactosamin-Schädi-
gung, untersucht und in Beziehung gesetzt zu der Synthese von Glykosaminoglykanen und Heparansulfat in
Hepatocyten, die aus diesen Lebern isoliert wurden. Gemessen an den biochemischen Kenngrößen der
Leberzelläsion im Serum (einige zytosolische und mitochondriale Enzyme, Gallensäuren) ist das Ausmaß der
mit beiden Lebergiften erzeugten Leberschädigung unter der Bedingung der akuten Entzündung stark
abgeschwächt. Es ergab sich eine inverse statistische Korrelation (r = —0,63 bis r = —0,84) zwischen der
funktionellen Konzentration eines Proteinaseinhibitor-Proteins, welches bestimmt wurde mit dem chromoge-
nen Substratässay für humanes a2-Makroglobulin -und den katalytischen Konzentrationen verschiedener
Zelläsionsenzyme im Serum lebergeschädigter Ratten, die gleichzeitig eine Terpentin-erzeugte Entzündung
hatten. Die starke Hemmung der Heparansulfat-Synthese in Hepatocyten von frühgeschädigten Lebern
(Syntheserate zwischen 0,2 und 0,4 der der KontrollzeUinkubationen) ist aufgehoben in Hepatocyten von
Lebern, die zwar der leberschädigenden Noxe exponiert waren* aber gleichzeitig eine akute Entzündung
hatten. Die letztgenannte Bedingung alleine verursachte eine l,8fache Steigerung der Heparansulfat-Synthese
in Hepatocyten. Heparansulfat war der einzige Typ von Glykosaminoglykanen, der unter allen Bedingungen
synthetisiert wurde. Die Ergebnisse werden diskutiert unter dem Aspekt der möglichen pathogenetischen
Rolle des Heparansulfates für Leberzellnekrosen.
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Introduction
Human and animal liver contains, with the exception
of keratan sulphate, the whole set of glycosaminogly-
cans and proteoglycans. The concentrations of these
compounds in tissue are normally rather low being
92 to 108 μηιοί hexosamine per g defatted dry weight
(1) and 160 to 230 μg uronic acid per g defatted dry
weight (2). The most prominent hepatic proteoglycan
is heparan sulphate, which resides preferentially at
the liver cell surface forming an important constituent
of the liver cell coat or glycocalyx (3). Although the
structural details of liver cell surface heparan sulphate
have been elucidated recently (4-7) the knowledge
on its physiological and pathobiochemical role is still
scanty. In accordance with a previously established
hypothesis, we propose for liver heparan sulphate a
significant role in the pathogenetic sequence of liver
cell injury (8). The assumption is based on the experi-
mental observation that the synthesis of both total
and liver cell surface heparan sulphate is inhibited
almost instantaneously after induction of toxic liver
injury by Z>-galactosamine (9) or thioacetamide (10,
11). Because of the extraordinarily high Ca2+-binding
capacity of N-sulphated (heparin-like) glycosamino-
glycans (12) this type of proteoglycan is most likely
responsible for the high concentration of Ca2+ at the
external cell coat (13). Its function s an ion filter
may hinder, together with other mechanisms, the
influx of Ca2+ into the cell and, thus, might be
responsible for the great intra-extracellular gradient
of this divalent cation. The disruption of the ion
gradient due to a highly increased intracellular Ca2+-
concentration is an early and according to several
reports likely causative event of liver cell necrosis
(14-20). The prompt loss of cell surface heparan
sulphate might be, according to this hypothesis, the
pathogenetic determinant for the fmally lethal entry
of Ca2+ into the injured cell. Consequently, livers
protected from toxic injuries might exhibit, despite
the application of the injurious agents, an unchanged
synthesis of heparan sulphate. To prove this assump-
tion we studied in hepatocytes from protected and
non-protected livers exposed to hepatotoxic chemi-
cals the synthesis of total glycosaminoglycans and of
heparan sulphate. As a model of liver cell protection
we evaluated in some details the beneficial effects of
"counter Irritation" on liver cell necrosis (21, 22).
It was reported that induction of inflammation by
intraperitoneal injection of BaSO4 apparently pro-
tects rats from £>-galactosamine provoked liver in-
juries (23). We extended the study on thioacetamide
injury, a quite differently acting hepatotoxic agent,
and applied turpentine s an inflammatory agent. In
addition, the degree of liver cell protection was re-
lated to the functional concentrations of some inhibi-
tors of proteinases.
Materials and Methods
Materials
Turpentine and D-galactosamine-HCl were obtained from C.
Roth KG, Karlsruhe, FRG; collagenase (type I from Clostri-
dium histolyticum) and calf thymus DNA were from Sigma
Chem. Co., Munich, FRG; DEAE sephacel was from Pharma-
cia Fine Chem. Uppsala, Sweden; thioacetamide p. a. was from
Merck AG, Darmstadt, FRG; sodium [j*S]sulphate (18.5-22.2
TBq/mol) was from New Engl. Nuclear Corp., Boston, USA,
and deoxyribonuclease (type I from bovine pancreas) was from
Boehringer Mannheim GmbH, FRG. The commercial sources
and specifications of all other reagents were s described else-
where(10, 11,24).
Treatment of rats
Male Sprague-Dawley rats (220—260 g body weight, Lippische
Versuchstieranstalt, Extertal, FRG) had free access to tapwater
but were deprived of food 12 h before Isolation of hepatocytes,
after subcutaneous injection of 0.5 ml of turpentine and after
Initiation of livef injury either by intraperitoneal injection of
thioacetamide (100 mg/kg body weight) or Z)-galactosamme
(500 mg/kg body weight), each freshly dissolved in saline.
Isolation and incubation of hepatocytes
Parenchymal liver cells were isolated by the method of Seglen
(25) incorporating slight m difications. The rats were anaesthe-
tized with an intraperitoneal injection of phenobarbital (Nem-
butal®, 54 mg/kg body weight) and the ver was preperfused
in situ via the portal vera in a noncirculating way for 10 min
with Ca2+-free Hank's balanced salt solution pH 7.4 at 37 °C
at a flow rate of 30 ml/min followed by recirculating perfusion
ex situ for further 15 min with Ca2+ (5mmol/l), collagenase
(0.5 g/l) and deoxyribonuclease (0.05 g/l) containing oxygenated
Hank's balanced salt solution (pH 7.4 at 37 °C) at a flow rate
of 50 ml/min. Thereafter, the liver capsule was gently removed,
the tissue was dissected and incubated in 100 ml collagenase-
containing oxygenated Hank's buffer for 10 min at 37 °C under
constant swirling, after which the material was filtered through
a double layer of sterile gauze. The initial cell Suspension
obtained in the filtrate was purified by differenti l ceiitrifuga-
tion, first for 2 min at 36 g and second two times for 2 min at
17g, each at 4 °C. The viability of the final parenchymal cell
Suspension, checked by trypan blue exclusion (2.5 g/l), was
between 80 and 90%, the cell recovery was between 2 · 108 and
5 · l O8 cells/liver, and the contamination with non-parenchymal
cells was less than 1%.
Incubation of hepatocytes and determination of
glycosaminoglycan synthesis
Suspensions of hepatocytes were incubated at 37 °C up to 8 h
in a total volume of 7.5 ml at a density of 3.3 χ ΙΟ6 cells per
ml in Dulbecco's modification of Eagles medium containing
1000 U/l penicillin and 100 mg/1 streptomycin and supple-
mented with L-glutamine (4mmol/l) and 250 M'Bq/1 of
[35S]sulphate. The Suspension was continuously gassed with a
mixture of 0.95 O2^0.05 CO2 at a flow rate of 10 ml/min and
mixed by an up-and-down eycle with a frequency of 12 min"1
(B hler Zellkultur-Anlage, T bingen, FRG). After incubating
the cells for various times with [35§]sulphate, aliquots of about
3 χ l O6 cells were aspirated and, after removal of a portion
for the determination of DNA, centrifuged (600 g, 5 min, 4 °C),
denatured for 5 min at 100 °C and thereafter proteolysed in
5 ml papain eontaining buffer (pH 6.2) for 48 h at 57 °C with
papain s described (10, 11, 26). The final proteolysate wais
coole4, centrifuged (2400 g, 5 min) and the superaataiit was
mixed for 10 min at pH 6.2 with 0.5%ml of DEAE-sephacel
•r
·· k
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(suspended in 0.3 mol/1 NaCl, pH 6.2) in the presence of
unlabeled glycosaminoglycans added äs carrier (10, 24). After
centrifugation (2400 g, 5 min) the supernatant was discarded,
the DEAE-sephacel was washed four times with 4 ml of 0.3
mol/1 sodium acetate, pH 6.2 and thereafter total glycosamino-
glycans were eluted with 2 ml of 2.2 mol/1 NaCl, of which
the radioactivity was measured in a Packard Crystal liquid
scintillation counter. Each incubation was performed in dupli-
cate; cells of treated animals were always incubated alongside
those of control livers.
Differentiation of total glycosaminoglycans was achieved by
selective degradation with nitrous acid to obtain heparan sul-
phate, by enzymatic hydrolysis with chondroitin AC- (EC
4.2.2.5) and ABC-lyases (EC 4.2.2.4) to obtain the incorpor-
ation of label into chondroitin sulphate and dermatan sulphate,
respectively, and by ion exchange chromatography on Dowex
1X2 (C1-) äs previously described (10, 11, 24, 26).
Determination of proteinase inhibi tor concentration
The concentrations of proteinase inhibitors in rat serum were
determined with chromogenic Substrate assays developed for
human a2-macroglobulin and arproteinase inhibitor (at-anti-
trypsin), respectively, äs described elsewhere (27) adopted to a
Cobas Bio centrifugal analyser (Hoffmann La Röche, Gren-
zach, FRG). The analytic critera of the procedure have been
reported (28).
Determination of serum bile acid concentration
Total bile acids were quantitated enzymatically (29) using a
reagent test kit from Merck AG, Darmstadt, FRG. The assay
was fully mechanized on a Cobas Bio centrifugal analyser; the
coefficient of Variation of the day-to-day imprecision was 6%
(x = 15 / ).
Determination of DNA
Cells of the Suspension were quantitated either by counting
with a haemocytometer (Neubauer chamber) or by fluorometric
determination of DNA (30) using calf thymus DNA äs a
Standard. For the latter assay the cells were disintegrated by
two cycles of freezing and thawing. The intra-series and inter-
series imprecision of the method are characterized by coeffici-
ents of Variation pf 4.2% and 7.5% (x = 350 g), respectively.
Determination of serum enzyme catalytic activity
concentrations
Blood was aspirated from V. cäVa inf. prior to the cannulation
of the portal vein for the Isolation of hepatocytes. The catalytic
cpncentrations of aspartate aminotransferase (EC 2.6.1.l)i al-
anme aminotransferase (EC 2.6.1.2), glutamate dehydrogenase
(EC 1.4.1.2), and alkah'he phpsphatase (EC 3.1.3.1) were deter-
mined in fully mechanized Systems (»Hitachi 737, Boehringer
Mannheim, FRG and Cobas Bio centrifugal analyser,
Hoffmann-LaRoche Grenzach, FRG) according to Standard
procedures (31). The activity of ornithine carbamyl transferase
(EC 2.1.3.3) (32) was assayed manually using a reagent test kit
from Bio Merieux, France.
Statistical analyses
The significance of differences was checked with the Mann-
Whitney-Wikoxon test; the .Statistical correlations were calcu-
lated with Standard procedures (33).
Results
Effect of acute inf lammation on toxic liver
cell injury
Acute inflammation induced by subcutaneous injec-
tion of turpentine results after 48 h in severe dysprote-
inaemia (not shown), in an increase of plasma fibrino-
gen from 1.5 ± 0.1 g/l to 4.5 ± 0.2 g/l, and in
elevated functional concentrations ranging from 12.7
± 0.9 kU/1 (controls) to 22.5 ± 3.5 kU/1 (p <0.005)
of a protein determined with the chromogenic sub-
strate assay for human a2-macroglobulin. The con-
centration of the protein measured with the corre-
sponding assay for human aj-proteinase inhibitor
remains unaffected (fig. 1). The turpentine-induced
increase in the proteinase inhibitor in rat serum,
designated here äs a2-macroglobulin, is strongly re-
duced or absent in rats having either Z)-galactosami-
ne- or thioacetamide-generated liver injury, which
suggests that the inhibitor protein is synthesized in
the liver. The view is supported by the decrease of
(X2-macroglobulin in serum of liver-injured rats (fig.
1).
The extent of biochemically monitored liver cell in-
jury initiated by a single dose of />-galactosamine
(fig. 2) and thioacetamide (fig. 3), respectively, is
effectively diminished in rats with acute inflamma-
tion. Whereas both the cytosolic (alanine aminotrans-
ferase and aspartate aminotransferase) and the mito-
chondrial (glutamate dehydrogenase, ornithine car-
bomyltransferase, aspartate aminotransferase) liver
cell enzymes exhibit significant (p = 0.005) elevations
of their catalytic serum concentrations in toxic liver
damages, the increase is only moderate in animals
pretreated with turpentine when compared with con-
trol rats, and for each parameter it is significantly (p
= 0.025) smaller than in those rats without inflamma-
tion (fig. 2, 3). Similar observations were made for
alkaline phosphatase. The concentrations of total bile
acids increase strongly and are more pronounced in
the thioacetamide than in the Z>-galactosamine type
of liver injury but remain almost unaffected in ani-
mals exposed to liver toxic agents in the presence of
acute inflammation (fig. 2, 3).
When the extent of liver damage is related to the
concentration of a2-macroglobulin in serum an in-
verse Statistical correlation between the catalytic con-
centrations of hepatocellular enzymes and the func-
tional concentrations of the proteinase inhibitor in
rat serum becomes evident (fig. 4). The degree of
negative correlation is obviously independent of the
subcellular localization of the enzyme in the liver cell,
i.e. it is similar for alanine aminotransferase and
ornithine carbamyltransferase.
J. Clin. Chem. Clin. Biochem. / Vol. 24,1986 / No. 11
Gressner and Pfeiffer: Preventive effects of acute iaflammation
2Θ
24
20
16
12
θ
4
0
" oc2-Mocroglobulin
τ
"ο
fl
8
"ο ο>
σ c
έ
·»-υσ
1=1
„Ι :Ξ S.
Ζ
C
CU
" c^-Proteinaseinhiibitor
ι χ ι ,=£=, κ&π ι ι ι ? ί ι ι ι
S «Λ C <«ο ^ c
"ο 2ί "ο « c ^ε Ο.Ε β« - gΒ! |to α =>
S
σ
| 28
υ
Ι 24
20
16
12
8
4
η
a2-M croglob
"r1· τ1 ιΙ
jlin
/
Ι ;
·;
Χ
b
c^-Proteinase inhibitor
.2 ο*
.c <JΗ- α
η=9 η=18 η = 5
.Ξ ο*
JC Οι— α
n = 9 n =18
O "2 3 t-
i^Z 3
n =5
Fig. 1. Functional concentrations of proteins in rat serum determined with the chromogenic Substrate assay for a2-macroglobulin
and arproteinase inhibitor, respectively. The animals were sacriflced 24 h after Injection of Z)-galactosamine and
thioacetamide and 48 h after application of turpentine. Rats receiving both turpentine and Z)-galactosamine or thioacet-
amide were injected with turpentine 24 h before application of the hepatotoxic agent. Contrpl rats received saline. The
mean concentrations ± S. D. of n independent experiments are given.
Changes of heparan sulphate synthesis in
hepatocytes of rats with acute and subacute
liver injury
Hepatocytes were isolated from rats injured for va-
rious times (up to 5 days) with a single dose of D-
galactosamine (500 mg/kg body weight). The cell
incubation was extended up to 8 h during which time
the vitality of the hepatocytes, s checked by trypan
blue exclusion, decreased from an initial 90% to
85%, the concentration of cell leakage enzymes in the
medium increased less than 20% (lactate dehydroge-
nase, aspartate aminotransferase) or remained almost
constant (alanine aminotransferase, glutamate dehy-
drogenase), and the incorporation of [35S]sulphate
into total glycosaminoglycans proceeded linearly (fig.
5). Twenty four hours after initiation of liver injury
the synthesis of glycosaminoglycans is severely de-
pressed, being (after a 8h incubation period) less
than 0.2 ofthat observed in the incubation of hepato-
cytes from control livers (fig. 5). Between 24 h and
48 h, glycosaminoglycan synthesis recovers and is el-
evated between 48 h and 120 h after initiation of liver
damage. The maximal increase is reached ftef 96 h,
at which time hepatocytes from treated livers incqr-
porate during a 8 h period about 1.5 times s much
[35S]sulphate into glycosaminoglycans s those from
control livers. Slightly less stimulated glycosamino-
glycan synthesis is observed between 48 h and 12 h
(not shown) after induction of injury (fig. 5). The
fraction of heparan sulphate synthesized in the hepa-
tocytes was determined both at various times of incu-
bation and in relation to the time after starting liver
injury. Under all conditions heparan sulphate rep=
resents between 0.85 and 0.92 of total [35S]labeled
glycosaminoglycans; the appearance of enzymatically
determined chondroitin sulphate and/or dermatan
sulphate was not evident. This was also proven by
nearly ideritical elution profiles of [3^S]labeled glyeo-
saminqglycans from Dowex 1X2 (fig.' 6) and DEAE-
sephacel anion exchanger. Thus, the time course given
in figure 5 for total glycosaminoglycans is almost
identical to that of heparan sulphate.
J. Clin. Chem. Clin. Bipchem. / Vol. 24,1986 / No. 11
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Fig. 2. Catalytic concentrations of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, glutamate dehy-
drogenase, ornithine carbamyl transferase, and substance concentration of total bile acids in serum of rats treated with
Z>-galactosaraine, turpentine and with a combination of both. The time sequence of injections and sacrifice were s
described in figure 1. The mean concentrations ± S.D. of n independent experiments are shown.
Effect of acute inflammation on the Inhibi-
tion of heparan sulphate synthesis in hepa-
tocytes from rats with acute liver injury
The results presented above for JO-galactosamine-
induced liver injury hold also true for another model
of toxic injury, i.e. thioacetamide-generated liver da-
mage (fig. T). Sppn after application of the noxious
agent the incorporation of [35S]sulphate into glycos-
aminoglycans is depressed (not shown); after 24 h the
amount of [35S]labeled glycosamiiioglycans synthe-
sized during a 4h incubation period is reduced by
more than 0.60 when compared with hepatocytes
from control rat livers. Interestingly, hepatocytes
from rats with a normal liver but acute inflammation
by turpentine, synthesized during the same period a
nearly 1.8 fold elevated amount of [35S]labeled glyco-
saminoglycans compared with control hepatocytes
(fig. 7). Parenchym l cells from livers exposed to
thioacetamide under acute inflammation reveal no
decrease of glycosaminoglycan production. Instead,
the incorporation of label is enhanced 3 fold and l .3
fold compared with hepatocytes from thioacetamide-
injured and control livers, respectively. Type-specific
analysis of hepatocellular glycosaminoglycans by en-
zymatic and chemical means and by anion exchange
chromatography reveals no changes of the profile of
newly formed [35S]labeled glycosaminoglycans. Under
each condition the fraction of heparan sulphate va-
ried between 0.85 and 0.90, and galactosamine-con-
taining glycosaminoglycans were not detected.
Discussion
Hepatocytoprotection is a promising field of research
in experimental hepatology, because it provides re-
sults of immediate consequence for the treatment and
prevention of human acute and chronic liver diseases
(34). The chemical nature of the cytoprotective drugs
is quite heterogeneous and ranges from eicosanoids
and related factors (35-40 a), synthetic terpenoid
compounds (41), ε-aminocaproic acid (42), putre-
J. Clin. Chem. Clin. Bioohem. / Vol. 24,1986 / No. 11
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Fig. 3. Catalytic concentrations of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, glutamate dehy-
drogenase, ornithine carbamyl transferase, and the concentration of total bile acids in serum of rats treated with
thioacetamide, turpentine and with a combination of both. The time sequence of injections and sacrifice were s described
in figure 1. The mean concentrations ± S.D. of n independent experiments are given.
seine (42), cholestyramine (43), heptanone derivatives
(44), and propylthiouracil (45) to some endogeneous,
s yet poorly defined proteinaceous compounds in
inflammatory exudates and sera (21—23, 46). The
effect of these and other hepatocytoprotectants is
mainly non-specific and, in most cases, not limited
to a certain type of chemical liver cell necrosis. Their
mechanism of action has been related to general s
yet poorly defined "stabilizing functions" on inner
and outer membrane structures (38,41), to the Inhibi-
tion of proteinases and esterases (46) known to be of
pathogenetic significance (47) and to their functions
s free radical scavengers, antioxidants and inhibitors
of lipid peroxidation (46, 48).
The model of hepatoprotection applied here utilizes
the beneficial effects on the liver of "counter irrita-
tion" (21-23), i.e. the generation of factor(s) in
serum or exudates by some unspecific irritants like
turpentine, which are known to have anti-inflamma-
tory potency (49 — 53). In most cases these endoge-
neous anti-inflammatory factors are proteins, of
which the synthesis in the liver is positively regulated
in acute phase conditions (54). In fact, protection of
the liver from the toxicity of £>-galactosamine by
competing unspecific injuries was ascribed to the ex-
cessive enhancement of the concentration of c^ma-
crofoetoprotein in serum (23). The c te phase pro-
tein was shown to have inflammation inhibiting
properties in the carrageenin type and other models
of non-specific inflammation (49, 50). Since turpen-
tine injection resulted in only a moderate increase in
the proteinase inhibitor (measured by its function
with a chromogenic Substrate developed for human
a2-macroglobulin), this (these) protein(s) must be dif-
ferent from authentic rat a2^macroglobulin (55) and
a2-macrofoetoprotein (23). The latter proteins, meas^
ured immunologically, rise several fold in seruin dur-
ing inflammation. However, s in the case of ά2-
macrofoetoprotein, we found an attenuation of liver
J. Clin. Chem. Clin. Biochem. / Vol. 24,1986 / No. 11
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Fig. 4. Correlatipns between the catalytic concentrations of
aspartate aminotransferase, alanine aminotransferase,
glutamate dehydrogenase, and ornithine carbamyl
transferase, respectively, and the functional concentra-
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of rats treated with turpentine followed 24 h thereafter
by an injection of 100 mg/kg body weight of thioacet-
amide. Animals were sacrificed 24h after application
of thioacetamide.
dainage that correlated directly with the increase in
the proteinase inhibitor. Futhermore, its increase fol-
lowing turpentine treatment was less in liver injured
rats. The latter observation points to the liver s
the source of the hepatoprotective agent. Thus, the
injured liver will lose its ability of seif protection
against noxious agents, which forms a pathogenetic
vicious circle, which results in an amplification of the
hepatpcellular toxicity of injurious drugs. Attempts
to isolate the protective protein(s) from acute phase
rat serum have been unsuccessful so f r (56).
t (h ]
Fig. 5. Time courses of the incorporation of [35S]sulphate into
total glycosaminoglycans of hepatocytes isolated from
rats injured for various times 24 h (n — n), 48 h (Φ — ^ ),
96 h (O - O), and 120 h(D- ) with a single dose of 500
mg/kg body weight of Z)-galactosamine. The results
are expressed relatively s fractions of the amount of
[35S]sulphate incorporated by cells from normal liver
during a 8h period (about 1.6 kBq/mg DNA) (Δ-
A). A representative experiment out of three is shown
(coefficient of Variation about 20%).
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Fig. 6. Elution profile from Dowex l X 2 of [35S]labeled glycos-
aminoglycans synthesized by hepatocytes from control
liver ( H ) and from livers damaged for 96Ti ( S ) and
*120 h ( 0 ) by a single dose of D-galactosamine. The
elution was performed with a stepwise gradient of in-
creasing NaCl concentrations, the radioactivity in the
effluent is expressed s a fraction of total eluted [J5S]la-
beledglycosaminoglycanradioactivity.
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Fig. 7. Effect of turpentine-induced acute inflammation on the
time course of the incorporation of [35S]sulphate into
total glycosaminoglycans of hepatocytes isolated from
control rats (receiving saline) ( — ), rats treated with
turpentine ( - ), with thioacetaraide (100 mg/kg
body weight) (o - o), and with a combination of turpen-
tine and thioacetamide (O — O). The time sequence of
injections and death was äs described in figure 1. A
representative experiment out of three is documented
(coefficient of Variation is 20%).
Liver damage, irrespective of the mechanism of action
of the various hepatotoxins, leads almost instan-
taneously after application of the drug to a severe
depression of heparan sulphate synthesis in hepatocy-
tes. The Inhibition occurs much earlier than any other
biochemical, morphological and clinical-chemical
sign of liver cell injury. This is substantiated by pre-
vious results obtained with liver slices and livers in
situ (9-11) and demonstrated here for hepatocytes
from livers exposed for 24 h to £>-galactosamine or
thioacetamide. Heparan sulphate synthesis was not
inhibited in hepatocytes from livers exposed to either
of these drug, if the rats were also subject to acute
inflammation. The latter condition prevents the de-
crease of cell surface bound heparan sulphate shown
previously to occur in early injured livers (8). This
effect may hinder the deleterious dearrangement of
intracellular Ca2+-homeostasis, which is thought to
be of great significance for irreversible cell injury
(14—20). Elevated intracellular calcium activates
phospholipases, which may further enhance the entry
of calcium into hepatocytes by degradation of phos-
pholipids of the plasma membrane (17). The mainten·^
ance of normal heparan sulphate synthesis in hepato-
cytes from livers exposed to jD-galactosamine in the
presence of acute inflammation is achieved although
the primary biochemical lesion of -P-galactosamine
in the cell, i.e. depletion of UDP-glucose, UDP-
galactose and other uracil nucleotides was reported
to occur in pfotected livers (23). Therefore, synthesis
of hepatocellular heparan sulphate obviously pro-
ceeds at a normal rate despite a depletion of UDP-
glucuronate, which was suggested to be the cause
for the severe Inhibition of hepatic heparan sulphate
production induced by D-galactosamine (17). Our
results also support the view that during the mem-
brane-stabilizing effect of certain hepatoprotective
factors generated in acute inflammatory conditioris,
the heparan sulphate composition of the cell coat is
normal. Clearly, the possibility cannot be excluded
that normal heparan sulphate synthesis in hepatocy-
tes from livers exposed to noxious agents is the conse-
quence rather than the cause of liver cell protection
by acute inflammation. However, a depression of
heparan sulphate synthesis in hepatocytes from drug-
exposed but protected livers, which was not observed
in this study, would strictly argue against the hypoth-
esis posed above (8). It should be noted here, but will
be reported in detail elsewhere (57), that turpentine
and other traumatic or inflammatory conditions sti-
mulate significantly the synthesis of heparan sulphate
in parenchymal liver cells. This type of glycosamino-
glycan is identified äs a novel, non-secreted and posi-
tively regulated acute phase reactant in rats. Future
studies are concerned with the elucidation of the
mechanism underlying the inflammatory response of
hepatocellular heparan sulphate synthesis and the
reversal of its depression in livers exposed to injurious
chemicals. In this respect, the role of certain secreta-
gogues of activated Kupffer cells (monokines) in the
Promotion of heparan sulphate synthesis in hepato-
cytes under these conditions deserves attention.
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